Mastermind-Like Domain-Containing Protein 1 (MAMLD1), also known as CXorf6, is a critical transcriptional coactivator that modulates the Notch signaling pathway and regulates steroidogenesis. Historically associated with congenital endocrine disorders such as hypospadias, recent oncology research highlights MAMLD1 as a key player in Notch-driven malignancies and endocrine-related cancers. Developing therapeutics against this intracellular target requires robust molecular tools to validate protein-protein interactions (PPI) and downstream gene transcription.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAMLD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAMLD1 Recombinant Protein (Mastermind-like domain) High purity (>95%), Endotoxin controlled (<1 EU/μg), Sequence Verified. Ideal for in vitro binding assays. |
View MAMLD1 Products |
| Gene Delivery | MAMLD1 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for stable cell line construction and nuclear translocation assays. |
View MAMLD1 Products |
| Benchmark Ab | Anti-MAMLD1 Recombinant Antibody Sequence-verified positive control for Western Blot, Immunofluorescence, and ChIP assays. |
View MAMLD1 Products |
| Validator | MAMLD1 siRNA Set Target-specific siRNA pool for knockdown validation and downstream target gene (e.g., CYP17A1) analysis. |
View MAMLD1 Products |
| Related Target A | NOTCH1 Core receptor in the Notch signaling pathway; co-activated by MAMLD1 complexes. |
View NOTCH1 Products |
| Related Target B | CYP17A1 Downstream steroidogenic enzyme regulated by MAMLD1 in Leydig cells. |
View CYP17A1 Products |
| Related Target C | NR5A1 Steroidogenic factor 1 (SF-1) that synergizes with MAMLD1 to regulate testosterone biosynthesis. |
View NR5A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular localization & complex formation | High-titer Lentivirus Premade Particles for stable expression and nuclear localization analysis. |
| Protein-Protein Interaction (PPI) screening | Sequence-verified, highly purified MAMLD1 functional domain proteins (>95% purity by SDS-PAGE). |
| Lack of reliable positive controls | Recombinant Benchmark Antibodies with fully defined sequences for reproducible assay baselines. |
| Off-target transcriptional effects | Validation-ready siRNA sets to confirm target-specific gene knockdown in cellular assays. |
Live MAMLD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MAMLD1 is an emerging frontier in precision medicine. As an intracellular transcriptional coactivator, MAMLD1 does not lend itself to traditional monoclonal antibody targeting. Instead, the global R&D pipeline is shifting toward small-molecule inhibitors of protein-protein interactions (specifically blocking the MAMLD1-Notch-RBPJ complex) and RNA-targeted therapeutics (siRNA/ASOs). In the oncology sector, researchers are investigating MAMLD1 inhibition as a strategy to overcome Notch-mediated drug resistance in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumors. Concurrently, its critical role in steroidogenesis positions it as a target of interest in endocrine-related pathologies and reproductive medicine.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Institutes, Biotech Startups | Notch-driven Cancers, T-ALL | In vitro binding assays requiring high-purity recombinant MAMLD1 target proteins. |
| RNA Therapeutics (siRNA/ASO) | Endocrine Research Labs | Adrenocortical Hyperplasia, Hypospadias Research | Sequence-verified siRNA controls and Lentivirus for target validation in primary cells. |
| Gene Therapy / Modulators | Translational Medicine Consortiums | Congenital Adrenal Disorders | High-titer Lentivirus for stable rescue and overexpression assays. |